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Abstract
Interaction between universities and companies is common in Countries considered to be developed and innovative. In 
Brazil, this strategy is not widely used, although some relevant actions have produced good results in the pharmaceutical 
sector. The Brazilian Innovation Law, which is considered a milestone, created the Technology Innovation Centers (TICs) 
in universities, and is seen by the Ministry of Health in Brazil as having great strategic promise within the area of drugs 
and medicine. In this regard, this article seeks to present the findings of an exploratory research project investigating the 
participation of Brazilian universities in the formation of strategic partnerships focused on the development of drugs, after 
the advent of the Brazilian Innovation Law. An exploratory study was used as an instrument of methodological support, 
backed by a survey whose results allowed the authors to identify some significant reflections structured in the university-
pharmaceutical industry-government approach.
Keywords: pharmaceutical industry; innovation; university-industry-government partnership; government innovation 
policy.
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the research, which fails to occur at the rate of production 
(CUATRECASAS, 2006).
In Brazil, the National Science, Technology, and Innovation 
Policy, of the Ministry of Health, aims for greater integra-
tion between academia and the industrial sector through 
the “implementation of policies for the development of 
healthcare production complexes, integrating and strength-
ening research and technology centers, official laboratories, 
institutions for higher education, middle school and voca-
tional training, and domestic companies, with emphasis on 
the research and production of drugs, products, processes 
and equipment for healthcare” (SAÚDE, 2008).
University-Pharmaceutical Industry Partnership
A research covering the years from 1993-2003 has shown 
the pharmaceutical sector has progressed a little – or al-
most nothing – during this period: the rate of importation 
was enormous and  no public policies were created to fo-
ment a significant change or recuperation in the sector 
(SILVA, 2007). Therefore, given the importance of innovation 
for the economy, the Innovation Law of 2004 was consid-
ered a breakthrough for the Brazilian Government, in the 
sense that it increases flexibility and the patent rights of the 
University, in addition to creating Technological Innovation 
Centers (TICs) in order to monitor the development stages 
of a project with potential interest for the private sector and 
facilitate technology transfer from the university to the busi-
ness sector, for example, through licensing (SBRAGIA, 2006). 
In universities without the management of TICs, a large 
number of patent requests is abandoned due to expira-
tion of payments (annuities) terms, while in the universities 
where research has been developed by means of a struc-
tured Technological Innovation Centers, the Index of Pat-
ents Granting of the universities showed significant increase 
(QUERIDO, 2011).
In the last decade, in the USA alone – which features cooper-
ation between universities and industry for R&D (SCHWAB, 
2010) – more than 1,000 partnerships were made between 
companies and Academia (ELMUTI, 2005). Support for re-
search and development activities and the time to market 
(TTM) of their results have already been a reality in many 
countries for many years, either through technology transfer 
centers linked to research institutions, or partnerships be-
tween universities and companies, and support for techno-
logical cooperation between companies (AVILA, 2004).
Success stories arising from partnerships between universi-
ties and the pharmaceutical industry abroad benefited soci-
ety in the form of drugs that are widely used today: patents 
of the anticoagulant Warfarin and Vitamin D (University of 
Wisconsin); of the antitumor agent Cis-platinum (Michigan 
Introduction
For the pharmaceutical industry, innovation is the keyword. 
Considered to be science-based, innovation is the key 
source of intra-industrial competitiveness, and it generates 
significant impacts on the public health of a Country (RA-
DAELLI, 2006), which becomes less dependent on foreign in-
novations (GREWAL, 2008). In addition, for the pharmaceu-
tical sector, product innovations (such as medications) have 
much more significant results than technological, marketing 
or process advances (GREWAL, 2008). 
It is only through drug innovation that patients can and do 
benefit from treatments that were unimaginable some time 
ago. There are still many diseases whose treatment is not 
yet perfect, suggesting that there is still much room for drug 
innovation. Without the efforts of companies and other 
stakeholders (ex. universities) to pay greater attention to 
Research and Development (R&D) in the sector, these ben-
efits would not be possible. (COMMISSION, 2009).
Aspects of Innovation in the Brazilian Pharmaceuti-
cal Industry
Although it ranks 8th in the world medicine market, Brazil 
has maintained its medication production by importing tech-
nology, due to its lack of history in innovation. This context 
demonstrates a fragile reality in the strategy of technologi-
cal development, since some knowledge must be developed 
internally. This is the teaching that international experience 
has demonstrated and the Country has the potential to 
share scientific and technological research activities, which 
have been restricted to the academic environment or gov-
ernmental institutions, not interacting with the business sec-
tor that generates wealth (VIEIRA, 2008).
It is extremely important that the pharmaceutical sector 
be prioritized by the Government as a strategic option for 
composing the Industrial, Technological and Foreign Trade 
Policy (PITCE). Under this policy, the R&D incentive is one 
of the foundations to substantiate this sector, which utilizes 
innovation as a key element for the growth of industrial and 
domestic competitiveness (SAÚDE, 2008). The willingness 
to differentiate products, to increment processes efficiency 
and to enter in new markets, represent the main reasons 
that have driven companies of the sample to innovate. On 
the other hand,  the main obstacle met by companies dur-
ing development and introduction of innovation is repre-
sented by the difficulties to establish partnership with other 
companies, by financial problems and lack of resources in 
the company (BIGLIARDI, 2011). Additionally, the business 
environment is not conducive to the research environment 
and the lack of a culture of innovation, coupled with the 
pressure to increase the portfolio of new products sacrifices 
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pirical findings (ELMUTI, 2005). Furthermore, there are still, 
traditionally, conflicts of interest, culture and objectives with 
the companies (LEE, 2000).
According to the president of the Association of National 
Pharmaceutical Laboratories (Alanac), in addition to bureau-
cratic obstacles, there should be more resources for funding 
and particularly greater synchronization between the pri-
vate sector and academia where “many resources are al-
located and not returned as products in the market”, says 
Geyer (GOLDBERG, 2010).
Given that the international community has recognized, for 
some time, the importance of universities for innovation, 
this article’s main objective is to present the findings of an 
exploratory study that investigated the participation of Bra-
zilian universities with regard to the formation of strategic 
partnerships focused on drug development, after the advent 
of the Brazilian Innovation Law. 
Materials and Methods
The study of the University-Company cooperative process 
is characterized, with regard to its nature, as descriptive, 
because it uses both quantitative and qualitative data. The 
qualitative and quantitative methods are not mutually ex-
clusive. The qualitative approach can be distinguished from 
the quantitative approach, but it would not be accurate to 
state that they are related by opposition. Although different 
in form and emphasis, the qualitative methods contribute to 
the research work a mixture of procedures that are both 
rational and intuitive in nature, and capable of contributing 
to a better understanding of the phenomena. 
The research was divided into two phases. The first phase 
was quantitative in nature, using survey questionnaires to 
collect data between the months of May and June of 2011. 
The Universities’ Technological Innovation Centers (TICs) 
were the primary focus of the investigation and the respec-
tive respondents. 
Although there are known difficulties in obtaining an ap-
propriate quantity of responses to the questionnaire, this 
method was chosen to provide a basis for answering the 
research hypothesis, in view of the positivist approach for 
the objective of this study.
The survey method seems the most appropriate for under-
standing the behavior of a relatively large population sam-
ple. In this phase, in order to analyze the questionnaire data 
(quantitative stage), the Statistical Package for the Social Sci-
ences (SPSS) program was used.
State University); of the vaccine against the Haemophilus 
bacteria that causes Meningitis (University of Rochester) 
and the antineoplastic drug Taxol® (Florida State Univer-
sity) (DEMAIN, 2001). In Brazil, the only exclusively Brazilian 
drug, the topical anti-inflammatory Acheflan, was created in 
partnership with four of the Country’s major universities 
(Federal University of Santa Catarina, Unifesp, PUC-Campi-
nas and Unicamp) (ACHÉ, 2011). Taking into consideration 
that big pharmas have held the largest amount of technologi-
cal capacities from the strategic alliances, in particular mole-
cules, it can be understood that their interest in participating 
in strategic alliances should be a way of reacting at internal 
and external changes, with the objective of keeping com-
petitiveness in the pharmaceutical market (OHABA, 2007).
With regard to the universities, some authors see this part-
nership as a possibility to generate technological innovation 
and intellectual property, contributing to socio-economic 
progress, while the involvement in a business environment 
enriches teaching. In addition, there is a real possibility to 
reduce the companies’ spending on Research and Devel-
opment (R&D) (SALOMON, 2008). In the biotechnology 
sector, for example, a study demonstrated lower spending 
when there is a company-university partnership, or rather, 
lower spending on R&D (GEORGE cited in ELMUTI, 2005).
Thus, the relationship between universities and companies 
has been identified as a source for new products and con-
sequently a factor for economic growth (DZISAH, 2008), 
as well as, through research programs, a method of solving 
practical business problems (ELMUTI, 2005).
The Problem situation
In Brazil, even with the Innovation Law, of the 315 compa-
nies that manufacture pharma-chemical and pharmaceutical 
products that implemented innovations, only 18 received 
governmental support for R&D through tax incentives, only 
14 of which made partnerships with universities (where 61% 
used the partnership for R&D and trials for product testing; 
the target of the pharmaceutical industries) (IBGE, 2010).
Paradoxically, the number of patents requested by universi-
ties has increased and the healthcare sector is greatly repre-
sented (SENNES; MENDES, 2009), which indicates that the 
universities are looking at the market in a more entrepre-
neurial manner, even if they are not proactively conducting 
market studies for technological demands (PEREIRA, 2009).
Nevertheless, the university-company interaction is insignifi-
cant and still faces many difficulties in its development. For 
this relationship to be successful, it is especially important 
that each side have the desire and willpower to make the 
relationship happen (SENNES, 2009). This is because the 
universities, for example, use basic research to contribute 
to the knowledge of new types of concepts, models and em-
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Validation and data collection
The pilot questionnaire was pre-tested with 5 (five) profes-
sionals (2 professors and 3 Masters students/PhD students) 
with both academic/research and academic/market experi-
ence. After analyzing the pilot pre-test, minor alterations in 
form, composition and organization were made, and then 
the final questionnaire was made available electronically on 
the Internet through research software. 
Thus, as an auxiliary tool used to collect data, the software 
SurveyMonkey@ (www.surveymonkey.com) was employed, 
which allows responses to be sent and received via the In-
ternet, enabling the participation of professional specialists. 
The questionnaire was available on the Internet between 
the months of May and June of 2011 and was mainly com-
posed of open and closed questions, in order to facilitate the 
collection and interpretation of data.
Thus, it included mandatory questions, multiple choice, semi-
open, dichotomous questions (Yes/No) and opinion grada-
tion using the Likert scale. Some open questions were used 
with the objective of obtaining “supplementary information” 
in case the respondent wishes to express an opinion rel-
evant to the topic. Following the Mattar guidelines (1996), 
identification of the respondents was requested only at the 
end of the questionnaire so that there is no risk of distorting 
the responses in the event that personal data was already 
provided at the beginning of the research.  
We sought to define a set of questions that required no 
longer than 15 minutes from the respondent, and used logi-
cal question sequencing, in order to direct the respondent 
based on the responses previously provided.
The 25 Technological Innovation Centers listed on the Min-
istry of Development, Industry and Foreign Trade website 
(www.mdic.gov.br) were considered and all of these TICs 
were contacted via E-mail.
Discussion and Analysis of Results
Field profile and analysis
Fifty six percent (56%) of the Technological Innovation Cent-
ers (TICs) responded to the research, a large majority of 
which were created after the Innovation Law (93%).
Of the TICs’ respondents, 66.7% have already worked and 
experienced the modus-operandi of a private institution and 
have worked in the TIC for more than 2 years, at least, and 
include: directors (8%), coordinators (33%), administrators 
(8%), professors (17%) and innovation agents (8%).
In the second phase, in order to include the qualitative ele-
ments, content research was conducted by the Technological 
Innovation Centers (TICs), also created by the aforemen-
tioned Law. Content analysis can be defined as an investi-
gative technique intended for the objective, systematic and 
quantitative description of the manifest content of commu-
nication.
Field Research and Analysis
In order to reach the objectives and answer the research 
questions, the questionnaire was developed by adapting the 
proposal presented by Bekkers and Freitas (2008) and Lee 
(2000) and organized by the author into 5 clusters: (1) in-
stitutional profile, (2) strategy, (3) government participation, 
(4) knowledge/technical capacity and, (5) university as a stra-
tegic partner, with the following objectives:
(1) Institutional Profile
Identify the profile of the studies made possible through the 
TICs and the temporal profile of the TICs after the Innova-
tion Law. Validate the respondent as an active participant of 
the TIC and identify whether or not they have experience in 
the private sector:
(2) Strategy
Measure how much time is dedicated to the applied research 
and how much the research made possible through the TICs 
is driven by the market; identify the companies’ profiles with 
regard to licensing options provided by the Innovation Law, 
from the perspective of the University.
(3) Government Participation
Measure the University’s perception with regard to the 
government’s involvement and promotion of medicines and 
the Government’s participation as a funder; identify gaps in 
government action in encouraging drug innovation by the 
Pharmaceutical Industries, from the universities’ perspective:
(4) Knowledge/Technical Capacity:
Identify if the studies made possible through the TICs are of-
ten patented prior to publication in scientific journals; iden-
tify the Universities’ perception with regard to knowledge 
transfer to businesses; identify the Universities’ perception 
with regard to their technical preparation in order to meet 
the requirements of the pharmaceutical companies in the 
stages of new drug development:
(5) University as a Strategic Partner
Measure the TIC’s perception with regard to their own pro-
fessional profile and enabler of partnerships with businesses; 
identify if the universities formed partnerships for new drug 
research, after publication of the Innovation Law:
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This finding provides further perspective on the Elmuti 
(2005) study, since he states that the Universities develop 
only basic research, not applicable to the market. However, 
this finding could result from a bias, since the research that 
reaches the TICs (which are not all of the studies developed 
within universities) already arrived with the purpose of be-
ing licensed for the market; a result of the entrepreneurial 
vision of the researcher. 
Based on this information and the data presented in Figures 
4 and 5, the responding TICs feature applied research and 
many of them cover the pharmaceutical sector, which can be 
fertile ground for attracting the interest of pharmaceutical 
companies interested in innovation. 
Thus, the profile demonstrates that the participation and in-
volvement of the respondents tends to be active in the TICs, 
which was favorable to the study objective.
Research in the area of pharmaceuticals, which is important 
for new drug development and the purpose of this work, 
was identified as one of the areas that most represents the 
research that reaches the TICs (27%).
Strategy
Compared to basic research, applied research was identified 
as having a greater frequency with regard to the type of re-
search that characterizes the responding TICs:
Figure 1: Research areas that represent the TICs. Source: The authors (2011)
Figure 2: Universities: applied research x basic research. Source: The authors (2011)
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Government participation
According to the results below, the responding TICs are pri-
marily funded by the Government.
However, there is not a consensus as to whether or not the 
Government is a facilitator for universities with regard to 
their encouragement of new drug research, given that the 
total number of respondents that believe the Government 
is a supporter equals the number of respondents that de-
scribed it as “indifferent” or “somewhat active”.
This information also indicates that there is a disconnect 
between the Government and universities for developing 
innovative drugs, which should be worked on to provide a 
favorable environment for innovation in this sector. If the In-
novation Law is viewed by the Ministry of Health (2008) as a 
great promise “whereby we hope to open a fruitful channel 
of collaboration between businesses and academic research 
institutions”, it is necessary to effectively direct the universi-
ties towards this objective.
However, with regard to the guidelines for researching new 
drugs, the TICs demonstrate divergent and unfocused opin-
ions:
In other words, there is not a consensus between the TICs 
regarding the factor that guides new drug research (if it is 
the government or the market). Other opinions mentioned 
were: “society’s demand”, “public universities”, “I don’t 
know”, “depends on the source of funds, could be the gov-
ernment or the market”, “by the needs verified by the gaps”. 
This demonstrates that, if it is not the source of funds, as 
one respondent points out, the universities are strategically 
not in line with the therapeutic needs of the market, nor 
the expectations of the Government’s public policies, which 
include drugs for neglected diseases. This disconnect is cor-
roborated by what was presented by Pereira (2009), where 
a lack of market research performed by the University is a 
reality. Thus, even with a growing number of patent requests 
made by universities, as shown by Sennes (2009), the re-
search cannot meet the expectations of the market.
Figure 3: Guidelines for drug research – viewpoint of the universities. Source: The authors (2011)
Table 1: TIC Funding. Source: The authors (2011)
Indicate approximately how much (in %) your university’s TIC was funded in the last 6 years:









Direct funding from the 
government 3 3 3 3 2.50
Indirect funding from the 
government 8 1 2 1 1.67
Commercial funding (financing 
agreement) 11 1 0 0 1.08
Private, non-profit research 
foundations 8 2 0 2 1.67
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As previously noted, the universities seem to not under-
stand the role that they should play in this context, since 
they are not aligned with the companies or the public health 
policies (Figure 6). Given the strong influence of the govern-
ment, primarily in the public universities, it is necessary that 
this link with the companies occurs through governmental 
policies focused on this purpose. 
In order to identify shortcomings in government actions, 
several factors were identified by the Universities as impor-
tant for the real incentive of drug innovation.
For the TICs, the best instruments for the government to 
increase and improve the research for drug innovation is to 
promote more innovation programs and more companies 
in the start-up phase, as well as provide tax breaks/ financial 
support.
Universities also believe that the government should bet-
ter support the organizations that perform R&D, instead 
How much does your TIC observe government incentives for new drug 







Table 2: Government incentive – Universities’ perspective. The authors (2011)
Figure 4: Instruments for the government to promote drug innovation. Source: The authors (2011)
of emphasizing the need to create a more entrepreneurial 
environment in academia and promoting partnerships with 
companies in order to develop orphan drugs.
Knowledge / Technical Capacity
According to the TICs, the Universities mainly expressed 
their knowledge through scientific documents, such as arti-
cles, publications in journals and lectures (4.00 on the Likert 
scale) as opposed to “grey literature”, such as patents (3.14 
on the Likert scale), even though some studies are available 
for licensing by the companies. 
From the TICs’ perspective, there are still significant barriers 
for knowledge transfer from the universities to the industry, 
which ends up using a very small amount of the knowledge 
available in universities. This is because it is difficult to over-
come culture factors between universities and the com-
pany’s commercial interests, since many partnerships are 
hindered by conflicts between Academia seeking to publish 
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through scientific publications. With regard to the promo-
tion of drug innovation, this could be an issue to be tackled 
by the Government, which localizes its resources to prior-
itize publications instead of aligning the applicability of the 
research to the needs of the market or the society.
This finding shows that the TICs’ vision is optimistic with re-
gard to partnerships with pharmaceutical companies, but it 
still needs better structural support to allow for a more en-
trepreneurial profile and, consequently, the implementation 
of more partnerships between universities and companies in 
favor of new drugs.
As for technical preparations for meeting the pharmaceuti-
cal market’s needs, see the graph below, where it appears 
the results and the company, which wants to patent the re-
search. Nevertheless, as discussed by Demain (2001), such 
sources of conflict can be bypassed in order to ensure the 
alliance’s success if the inventions have their patent applica-
tion filed immediately so that the study can then be made 
available to the scientific community. 
However, the universities realize that conducting this type of 
contract brings income to the university and disagree that 
this type of partnership cannot contribute to the develop-
ment of research and that the industry will not be interested 
in the knowledge developed in the university.
Universities recognize that there is not incentive for co-
operating with the industry, since the results are measured 













There are still significant barriers for knowledge 
transfer from universities to the industry 0 1 0 6 5 4.25
Private companies make very little use of the 
knowledge available in universities 1 2 0 7 2 3.58
Cooperation with the industry is hindered by 
cultural factors, or rather, differences between 
Academia and commercial interests
1 3 1 3 4 3.50
Many partnerships are hindered by conflicts 
between Academia, which seeks to publish the 
results and the company, which wants to patent 
the research
1 2 1 6 2 3.50
There is no incentive to cooperate with the 
industry; the university’s results are measured 
through scientific publications
1 3 1 4 3 3.42
It is difficult to find partners in the private 
industry for R&D partnerships 0 6 1 3 2 3.08
Companies do not want to cooperate with R&D 
in the universities; they only want to absorb our 
knowledge
2 4 1 5 0 2.75
Transferring knowing to the industry is very 
costly for the universities (in terms of time and 
money)
4 5 1 1 1 2.17
The industry is not interested in the knowledge 
developed in the universities 6 5 0 1 0 1.67
The knowledge flows from the industries to the 
universities 7 3 1 1 0 1.67
The universities are not willing to spend time and 
money transferring their knowledge to industries 8 3 0 0 1 1.58
Conducting research contracts with companies 
brings income to the university, but this type of 
research does not contribute to the development 
of research
10 1 0 1 0 1.33
Table 3: Knowledge transfer with companies – universities’ perception Source: The authors (2011)
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Thus, the results of this study show that although most of 
the studies that reach the TICs to be licensed are in the 
pharmaceutical area and are based on applied research, 
partnerships with private companies after the Innovation 
Law were poorly represented.  While the representatives 
of the TICs believe that the universities feature the tech-
nical ability and knowledge to contribute to any stage of 
new drug development, there is no guidance for this type 
of research since it lacks cooperative involvement between 
the universities, the needs of market and the government’s 
healthcare policies. The data also showed that the TICs be-
lieve that partnerships with the private sector still present 
difficulties, but they can bring new experiences and income 
to Academia, whose government incentive for drug research 
and development, which can bring practical improvements 
to healthcare and quality of life, is still unsubstantial. 
Conclusions
This study resembles, in a general way, the Brazilian empirical 
studies that discuss the partnership between universities and 
companies, aiming to contribute, in a more specific way, to 
the sectoral study of the Brazilian pharmaceutical industry, 
one of the priorities of innovation in the Country. This re-
search shows that the TICs formed few partnerships/licensing 
with private drug companies after the Innovation Law and 
still believe there to be strong barriers with the private sec-
tor, despite real cases of success achieved in the market; the 
objective of this partnership. A more direct support is needed 
for the TICs, which should have greater autonomy and par-
ticipation with the University, such as the American offices of 
technology transfer that actively seek technology developed 
by the universities to bring to the market, raising funds for the 
development of further research within the university. 
that almost all of the companies’ strategic needs can be met 
by the Universities.
Thus, from the perspective of the TICs, for the development 
of new drugs, the University is capable of conducting, pri-
marily, research for the development of new formulations 
of medicines, pre-clinical trials (in animals), followed by syn-
thesis/creation of new therapeutic molecules, in addition to 
in-depth research of diseases to be treated, in this order. 
The University as a strategic partner
From the viewpoint of the Universities, in the past 6 years, 
partnerships for new drug R&D did not occur very often 
with private companies, which is confirmed by the IBGE 
(2010) data.
In order to identify the perception of the University itself, 
through the TICs, with regard to its preparation for meeting 
the needs of the pharmaceutical market, the graph below 
shows that the universities believe they advertise their ser-
vices and they are easily accessible. They also believe that 
their physical resources are relevant and they have access 
to researchers with highly qualified “know-how” and the ex-
pertise and reputation to develop research and meet the 
companies’ expectations, which can paint a better picture 
for the companies and reduce costs and/or risks.
However, the universities, through the TICs, disagree that 
they cannot guarantee confidentiality/patent protection, 
that they are slow or bureaucratic, that they have long-term, 
non-feasible projects, and that they are unpredictable or 
lacking professionalism.
Figure 5: Development of new drugs – universities’ technical capacity. Source: The authors (2011)
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In the last 6 years, indicate the frequency with which your university’s TIC formed a partnership for drug 
R&D
Responses Never Occasionally Frequently Always Likert Scale
Other Universities or higher education 
institutions
2 5 3 2 2.42
Governmental institutions or private non-
profit research institutions 3 6 2 1 2.08
Private companies 3 6 2 1 2.08
Other departments within the university 5 4 2 1 1.92
Commercial manufacturer or service providers 
(except consultants)
7 3 1 1 1.67
Did not form a partnership in this area
7 4 0 1 1.58
Consultants (individuals or through firms) 7 4 1 0 1.50
Table 4: Frequency of TIC partnerships for drug R&D.
Table 4: Frequency of TIC partnerships for drug R&D.Figure 6: Universities as strategic partners
Government still needs to encourage a new way of measur-
ing Academia’s results and be more assertive in relation to 
the goals and drug innovation programs within the universi-
ties, where the results are still (mostly) measured through 
scientific publications and where many studies are developed 
(and sometimes patented), but did not arouse the interest of 
any stakeholders.
The TICs, in turn, seem to not know the real market de-
mands or the demands of the public healthcare system, 
including with regard to neglected diseases. It is therefore 
necessary that the Universities become part of the Triple 
Helix model and become more active in this context, seek-
ing closer ties with the Government and the market needs, 
demanding a paradigm shift, including changes in procedures 
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